This announcement is a separate document:
アステラス製薬：中国の国家医薬品管理局は、局所進行または転移性尿路上皮がんの治療薬としてPADCEVを承認しています
Astellas Pharma: China's National Medical Products Administration has approved PADCEV as a treatment for locally advanced or metastatic urothelial carcinoma.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.